VA
SUPN icon

Vident Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Vident Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,467
Closed -$596K – 1736
2025
Q3 		$596K Sell
12,467
-1,783
-13% -$71.8K 0.01% 1104
2025
Q2 		$449K Sell
14,250
-636
-4% -$20.4K 0.01% 1121
2025
Q1 		$488K Buy
14,886
+494
+3% +$17.5K 0.01% 1044
2024
Q4 		$520K Buy
14,392
+309
+2% +$10.9K 0.01% 919
2024
Q3 		$439K Sell
14,083
-8,793
-38% -$274K 0.01% 1001
2024
Q2 		$612K Buy
22,876
+7,713
+51% +$224K 0.02% 789
2024
Q1 		$517K Buy
15,163
+1,332
+10% +$39.7K 0.01% 810
2023
Q4 		$400K Buy
13,831
+2,879
+26% +$76.3K 0.01% 880
2023
Q3 		$302K Buy
+10,952
New +$333K 0.01% 900

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's SUPN Position: Q4 2025 in Review

Vident Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 12,467 shares — an estimated $596K sold.

Vident Advisory first reported a position in SUPN in Q3 2023 and held it in 9 quarters. The position peaked at $612K in Q2 2024. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Vident Advisory reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Vident Advisory sold 12,467 Supernus Pharmaceuticals shares in Q4 2025, an estimated $596K.
  • Vident Advisory first reported a position in Supernus Pharmaceuticals in Q3 2023 and held it in 9 quarters.
  • Vident Advisory's Supernus Pharmaceuticals position peaked at $612K in Q2 2024.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Vident Advisory's 13F filing for Q4 2025, filed 18 Feb 2026.